American Society of Hematology Annual Meeting

Data demonstrate that iberdomide alone or in combination with other treatments may be a promising option for patients with relapsed/refractory lymphoma.

Adults with graft-versus-host disease who were treated with a three-drug regimen with cyclophosphamide after transplant may have improved survival rate compared with those treated with a two-drug regimen.

Progression-free survival and overall response rates greatly improved in patients with CLL/SLL treated with Brukinsa compared with Imbruvica.

Patients with chronic lymphocytic leukemia tended to switch to another regimen or intensify their Calquence treatment quicker than those given Imbruvica, study results showed.

An expert from the Mayo Clinic explained that the use of a combination of drugs including Darzalex in the first-line setting may lead to better outcomes for patients with multiple myeloma instead of other first-line standard-of-care options.

Treatment with the CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) led to a 97.9% response rate at two years in patients with relapsed/refractory myeloma in a recent clinical trial.

Two different doses of Venclexta combined with Darzalex and the steroid dexamethasone elicited effective responses appeared safe in patients with t(11;14) relapsed/refractory multiple myeloma.

The data demonstrated that the combination of Imbruvica and Rituxan conferred superior progression-free survival results in patients with previously untreated chronic lymphocytic leukemia, compared with the chemotherapies fludarabine and cyclophosphamide plus Rituxan.

The use of a novel drug combination yielded positive outcomes in patients with B-cell lymphomas for whom CAR-T cell therapy or stem cell transplant isn’t an option.

Most patients with acute myeloid leukemia and myelodysplastic syndrome achieved strong antibody responses to COVID-19 vaccination, according to recent study results.

Treatment with Ninlaro plus Darzalex and a low dose of the steroid dexamethasone was associated with favorable responses to treatment in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma.

Patients with chronic lymphocytic leukemia reported improved quality of life when treated with frontline Imbruvica and Rituxan, followed by continuous treatment with Imbruvica.

Patients with relapsed or refractory multiple myeloma experienced a benefit after receiving Xpovio in combination with Darzalex, Velcade and the steroid dexamethasone.

The immunotherapy Kymriah offered similar benefits in patients younger than and older than 18 years with relapsed/refractory B-cell acute lymphoblastic leukemia.

Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.

Using the presence of minimal residual disease to direct Imbruvica plus Venclexta treatment appears to be a feasible option for patients with relapsed/refractory chronic lymphocytic leukemia.

Recent results demonstrated durable responses and no new side effects for Venclexta plus Imbruvica in pretreated chronic lymphocytic leukemia.

Patients with large B-cell lymphoma tended to have better quality of life that continued to improve over time after receiving Breyzani compared to those given standard of care.

In recent trial results, a dose reduction of Xpovio (selinexor) was associated with longer progression-free survival and duration of response while also reducing side effects in patients with multiple myeloma.

More than half of the patients (66.7%) in the Venclexta and Rituxan arm who went on to receive subsequent Venclexta-based treatments experienced a partial response or partial nodal response to the therapy.

Among 27 patients with relapsed/refractory chronic lymphocytic leukemia patients who completed all 12 cycles of the triplet therapy, 100% of patients had a complete or partial response to the treatment—with 41% achieving a complete response.

The combination of ublituximab and umbralisib, two novel compounds, was able to safely prolong progression-free survival with low rates of toxicities in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy regardless of prior treatment.

At a median follow-up of 25.9 months, 17% of the patient population who received Calquence monotherapy experienced a cardiac toxicity of any severity, which led to treatment discontinuation in only seven patients.

The early study of the investigational CAR-T cell therapy lisocabtagene maraleucel shows how patients with relapsed/refractory CLL/SLL may have a viable new treatment option.

This data, according to a resident physician at Brigham and Women’s Hospital, highlights the need for systematic mental health screening and management for individuals with blood cancers.

In an interview with CURE®, a Waldenstrom’s macroglobulinemia expert discusses the long-term benefits of the targeted combination of Imbruvica and Rituxan.

Patients with aggressive lymphomas experienced sharp increases in quality of life from time of diagnosis until one year later and continued to see improvements for almost a decade.

Imbruvica treatment in patients with chronic lymphocytic leukemia whose disease expressed a certain mutation elicited sustained efficacy over a median follow-up of four years, according to data from a long-term analysis.

In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.

The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.